Journal
JOURNAL OF CONTROLLED RELEASE
Volume 105, Issue 3, Pages 240-248Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2005.03.022
Keywords
buccal mucosa; permeability; triamcinolone acetonide; Azone (R); local drug delivery
Ask authors/readers for more resources
In this study, the buccal mucosal uptake and retention of triamcinolone acetonide (TAC) were assessed in the presence of the skin penetration enhancer, Azone (R) (AZ). Porcine buccal mucosa was excised, mounted in modified Ussing chambers, and pretreated with ethanolic solutions of AZ. After 2 h, the rate of TAC disappearance from the donor chamber and TAC appearance in the receptor chamber was monitored, and the mucosal retention of TAC was determined at the completion of the experiment. The permeability and mucosal uptake of TAC was also determined using the TAC-containing proprietary product, Kenalog (R) in Orabase (R) (KO), in the presence and absence of AZ. Pretreatment of the buccal mucosa With AZ increased the TAC disappearance permeability coefficient from 4.78 +/- 0.31 x 10(-5) cm/s to 7.12 +/- 0.53 x 10(-5) cm/s. While the TAC appearance permeability coefficient was also enhanced 3.8-fold, a 4.4-fold increase in the tissue concentration of TAC was observed. Incorporation of AZ into KO did not result in an enhanced tissue concentration of TAC, however, when the tissue was pretreated with AZ, significantly higher amounts of TAC accumulated in the tissue. Pretreatment of the buccal mucosa with A-Z results in increased tissue concentrations of TAC, which may be of clinical benefit in the treatment of oral mucosal inflammatory conditions. (c) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available